OpRegen: A New Treatment for Dry AMD
If you’re over 50, and suffer from dry AMD (dry form, age-related macular degeneration), you may be eligible to join our clinical trial using RPE cell transplantation to treat dry AMD. Please see our clinical trial sign-up page.
OpRegen is a proprietary formulation of human embryonic stem cells (hESC) and derived retinal pigmented epithelial (RPE) cells, developed to address the unmet medical needs of people suffering from age-related macular degeneration (AMD). RPE cells are critical in nourishing and supporting the retina. When these cells are lost due to age, patients suffer from AMD, leading to severe vision loss and sometimes blindness.
OpRegen provides RPE cells in a suspended form to replace those lost due to AMD. It’s among the first hESC-based products to reach clinical trials.
AMD is the leading cause of blindness and visual impairment in the aging population; 30% of Americans aged 75 and older have some form of AMD. The U.S. Centers for Disease Control and Prevention estimate that about 1.8 million people in the United States have advanced stage AMD and another 7.3 million have an earlier stage and are at risk of vision impairment from the disease. Most people are afflicted with the dry form of the disease, for which there is currently no effective treatment. To learn more about AMD, please visit the National Eye Institute.